Fig. 1 · Structure
Documents & Downloads
VK-2019
EBNA1 Inhibitor
VK-2019 is an orally bioavailable selective inhibitor targeting the Epstein-Barr virus nuclear antigen 1 (EBNA1). By disrupting the protein-DNA interface, VK-2019 interferes with the recruitment of viral DNA replication machinery, effectively blocking EBV replication in latently infected cells. This compound has been shown to reduce the copy number and gene expression of Epstein-Barr virus, decrease EBER-positive cells, and exhibit significant antiviral, immunomodulatory, and antiproliferative effects. In vivo studies demonstrate that VK-2019 inhibits tumor growth in EBV-dependent xenograft models, making it a valuable tool for research in advanced nasopharyngeal carcinoma and various EBV-associated malignancies.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Inhibitor |
| CAS Number | 2044520-06-9 |
| Applications | EBNA1 Inhibitor |
| Formula | C29H25NO4 |
| Molecular Weight | 451.51 |
| SMILES | O=C(C1=C(C2=CC3=C(C=CN3)C=C2)C(C#CC4=CC=C(COC5CCOCC5)C=C4)=CC=C1)O |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.